[First Release] The first "digestive endoscopic surgery robot" enters the final stage of clinical trials, ROBO Medical receives tens of millions of yuan in Series A financing

Artery Network learned for the first time that Shenzhen Robo Medical Technology Co., Ltd. ("ROBO Medical" for short) has recently completed tens of millions of yuan in Series A financing. This round of financing was led by Taikun Fund and Kangjian International Medical The group followed the investment. The funds raised will be used to conduct clinical trials of the digestive endoscopic surgical robot product "ROBO Medical" and to develop new products.

ROBO Medical is a pioneer in surgical robots in the field of digestion. It has been committed to technological research on flexible digestive endoscopic surgical robots. It is also the first surgical robot company in the world to enter the industrialization stage in this field, and is in a leading position with its American counterparts.

So far, ROBO Medical’s self-developed digestive endoscopic surgery auxiliary robot system has carried out clinical trials in many centers such as Shandong University Qilu Hospital and Shanghai Changhai Hospital. More than 100 operations have been performed, and the clinical trial enrollment has come to an end.

The incidence of digestive tract tumors is high, and ESD surgery is difficult to popularize

According to relevant data from the World Health Organization, the incidence and mortality of digestive tract tumors are increasing globally, and nearly half of the patients with digestive tract tumors are located in China. There are more than 1.36 million new cases in China every year, accounting for about 30% of new cancers. Digestive tract tumors have become the number one cancer in my country.

In recent years, with the promotion of the concept of “early screening, early diagnosis, and early treatment”, endoscopic submucosal dissection (ESD) has become the preferred treatment option for early gastrointestinal cancer.

However, according to relevant statistics, the coverage rate of doctors who can perform ESD surgery in China is only 19 people/million people. Compared with Japan, the coverage rate of doctors is 181 people/million people, which is almost 10 times that of China. . The high difficulty and long learning curve of traditional ESD surgery are the main reasons that limit its popularization.

Cooperate with Qilu Hospital of Shandong University to develop to fill the gap in digestive endoscopic surgery robots

ROBO Medical is keenly aware of the clinical needs and market gaps in this field.

In 2017, ROBO Medical cooperated with Qilu Hospital of Shandong University to develop a digestive endoscopic surgical robot, and undertook the "Key R&D Plan of the Ministry of Science and Technology - Key Technologies and Systems for Minimally Invasive Surgical Robots for Digestive Endoscopy" and is committed to transforming surgical robots into Technology is applied to the field of digestion.

ROBO Medical Digestive Endoscopic Surgery Assisted Operating System

According to reports, ROBO Medical adopts a leading micro-continuum flexible robotic arm solution, whose diameter can reach within 3mm, which can achieve precise master-slave control while completing 6 degrees of freedom movement. By replacing the traditional gastroscopy movement with the movement of the robotic arm, the operation of digestive endoscopic surgery is closer to the doctor's intuition, thereby shortening the operation time, reducing intraoperative complications, and expanding the scope of the operation.

About Taikun Fund

Taikun Fund is a biomedical industry fund jointly established by Tigermed, Hangzhou Capital and Hanggao Technology Innovation, with a fund management scale of 20 billion yuan. Taikun Fund relies on Tigermed's clinical CRO industrial layout, complies with the development strategy of Hangzhou's pharmaceutical industry, adopts market-oriented operations, and focuses on the life and health industry, focusing on innovative medical devices, biomedicine, medical services, medical informatization, and digital therapy. , intelligent manufacturing, nutrition and health companies, etc., are committed to building a scientific, cross-cycle value investment platform for the biomedical industry.

The above is the detailed content of [First Release] The first "digestive endoscopic surgery robot" enters the final stage of clinical trials, ROBO Medical receives tens of millions of yuan in Series A financing. For more information, please follow other related articles on the PHP Chinese website!